These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 17400453

  • 1. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
    Hidaka K, Kimura T, Tsuchiya Y, Kamiya M, Ruben AJ, Freire E, Hayashi Y, Kiso Y.
    Bioorg Med Chem Lett; 2007 Jun 01; 17(11):3048-52. PubMed ID: 17400453
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
    Abdel-Rahman HM, Kimura T, Hidaka K, Kiso A, Nezami A, Freire E, Hayashi Y, Kiso Y.
    Biol Chem; 2004 Nov 01; 385(11):1035-9. PubMed ID: 15576323
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes.
    Nöteberg D, Hamelink E, Hultén J, Wahlgren M, Vrang L, Samuelsson B, Hallberg A.
    J Med Chem; 2003 Feb 27; 46(5):734-46. PubMed ID: 12593654
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
    Ersmark K, Nervall M, Gutiérrez-de-Terán H, Hamelink E, Janka LK, Clemente JC, Dunn BM, Gogoll A, Samuelsson B, Qvist J, Hallberg A.
    Bioorg Med Chem; 2006 Apr 01; 14(7):2197-208. PubMed ID: 16307884
    [Abstract] [Full Text] [Related]

  • 14. Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum.
    Miura T, Hidaka K, Azai Y, Kashimoto K, Kawasaki Y, Chen SE, de Freitas RF, Freire E, Kiso Y.
    Bioorg Med Chem Lett; 2014 Apr 01; 24(7):1698-701. PubMed ID: 24631188
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.
    Zhang M, Nguyen JT, Kumada HO, Kimura T, Cheng M, Hayashi Y, Kiso Y.
    Bioorg Med Chem; 2008 May 15; 16(10):5795-802. PubMed ID: 18400502
    [Abstract] [Full Text] [Related]

  • 20. Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs'.
    Romeo S, Dell'Agli M, Parapini S, Rizzi L, Galli G, Mondani M, Sparatore A, Taramelli D, Bosisio E.
    Bioorg Med Chem Lett; 2004 Jun 07; 14(11):2931-4. PubMed ID: 15125962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.